Nanobiotix/$NBTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ticker
$NBTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
108
Website
Nanobiotix Metrics
BasicAdvanced
$335M
-
-$1.65
1.55
-
Price and volume
Market cap
$335M
Beta
1.55
52-week high
$7.29
52-week low
$2.76
Average daily volume
5.5K
Financial strength
Current ratio
1.043
Quick ratio
0.977
Long term debt to equity
-69.977
Total debt to equity
-77.472
Interest coverage (TTM)
-8.44%
Profitability
EBITDA (TTM)
-77.259
Gross margin (TTM)
100.00%
Net profit margin (TTM)
947.59%
Operating margin (TTM)
949.35%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
-$79,920
Management effectiveness
Return on assets (TTM)
-52.89%
Return on equity (TTM)
201.73%
Valuation
Price to revenue (TTM)
-39.754
Price to book
-4.42
Price to tangible book (TTM)
-4.42
Price to free cash flow (TTM)
-14.012
Free cash flow yield (TTM)
-7.14%
Free cash flow per share (TTM)
-0.493
Growth
Revenue change (TTM)
-119.86%
Earnings per share change (TTM)
33.47%
3-year revenue growth (CAGR)
39.53%
10-year revenue growth (CAGR)
10.01%
3-year earnings per share growth (CAGR)
2.08%
10-year earnings per share growth (CAGR)
6.86%
What the Analysts think about Nanobiotix
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Bulls say / Bears say
Regulatory harmonization in Europe reclassifying JNJ-1900 (NBTXR3) as a medicinal product and filing a new composition-of-matter patent strengthens global IP protection and may accelerate market approval and reimbursement.
Phase 1 pancreatic cancer study results showed median overall survival of 23 months versus historical 19.2 months with a favorable safety profile, supporting further development in this high-need indication.
Johnson & Johnson’s dosing of the first patient in the randomized Phase 2 CONVERGE NSCLC trial expands the clinical pipeline and validates external commitment to NBTXR3’s lung cancer programs.
Nanobiotix reported a net loss of €68.1 million for FY 2024 and held €49.7 million in cash at year-end, with Q1 2025 cash down to €39.8 million, suggesting potential dilution or financing risk as runway approaches mid-2026.
Amendment to the global licensing agreement with Johnson & Johnson reduced overall deal value by $105 million, lowering potential future milestone payments and capping upside from lead programs.
The pivotal Phase 3 NANORAY-312 trial for head and neck cancer remains pending interim analysis after global sponsorship transfer by Q3 2025, posing timeline and clinical execution risks.
Data summarised monthly by Lightyear AI. Last updated on 23 Jul 2025.
Nanobiotix Financial Performance
Revenues and expenses
Nanobiotix Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $335M as of August 01, 2025.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of August 01, 2025.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.